All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @pagingdrfran on Instagram · 65s|Watch on Instagram
Full video transcriptClick to expand

Auto-generated transcript of @pagingdrfran's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00For some patients, combined hormonal birth control pills are a great form of hormone replacement therapy
  2. 0:05in perimenopause and menophause. I like to think of this as a nice like three-in-one situation,
  3. 0:09so not only do you have your estrogen in those pills, that's going to help manage some of your
  4. 0:12symptoms, but you also have a form of progester which is going to help protect your uterus.
  5. 0:16And on top of that, you have a form of contraception to help protect you from pregnancy, because yes,
  6. 0:20you can still get pregnant in perimenopause. For some patients though, the estrogen in those
  7. 0:24combined pills are not going to be enough to help manage their symptoms. And so for my patients,
  8. 0:28under 50, who are no longer having their symptoms managed by traditional birth control pills,
  9. 0:33we talk about transitioning to hormone replacement therapy. For those patients who are still perimen
  10. 0:38opausal, I also talk about using a marina at UD as their form of progestin, because again,
  11. 0:43we're trying to prevent pregnancy while using the estrogen, patch, or pill to help manage your symptoms.
  12. 0:48A lot of people talk about transitioning from birth control pills to traditional hormonal
  13. 0:52placement therapy after the age of 50. Over the two times that we're going to talk about
  14. 0:55transitioning from birth control pills to traditional hormonal placement therapy is if your symptoms
  15. 0:59aren't being managed by the combined hormonal birth control pills, or if you're over 50.

@pagingdrfran's birth control for perimenopause advice checked

Dr. Fran (DO, FACOG)

Instagram creator

31.7K viewsView on Instagram

Quick answer

Combined oral contraceptives are a recognized but higher-risk option for perimenopausal symptom management compared to traditional HRT formulations using estradiol, due to the synthetic ethinyl estradiol component and elevated VTE risk. The video's recommendation to transition to standard HRT when symptoms are uncontrolled or at age 50 aligns with NAMS and British Menopause Society guidance, though individual cardiovascular risk stratification is essential before initiating or continuing COCs in women over 40. The Mirena IUD as a progestin source in combination with systemic estrogen is a well-documented clinical strategy for women requiring concurrent contraception.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @pagingdrfran's birth control for perimenopause advice checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@pagingdrfran's birth control for perimenopause advice checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@pagingdrfran's birth control for perimenopause advice checked" from Dr. Fran (DO, FACOG). We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Combined oral contraceptives are a recognized but higher-risk option for perimenopausal symptom management compared to traditional HRT formulations using estradiol, due to the synthetic ethinyl estradiol component and elevated VTE risk.

The reason this review is not generic is the source wording and the canonical claim label "trt birth control pills for perimenopause and when it s time to." In this clip, the useful excerpt is: "For some patients, combined hormonal birth control pills are a great form of hormone replacement therapy in perimenopause and menophause." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

NAMS 2022 guidelines confirm low-dose COCs are an acceptable perimenopausal option for vasomotor symptom control in women without contraindications, supporting the video's core premise.
People who land here are usually comparing the Testosterone claim with perimenopause, birthcontrolpills, and hormonereplacementtherapy.
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Combined oral contraceptives are a recognized but higher-risk option for perimenopausal symptom management compared to traditional HRT formulations using estradiol, due to the synthetic ethinyl estradiol component and elevated VTE risk.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Combined oral contraceptives are a recognized but higher-risk option for perimenopausal symptom management compared to traditional HRT formulations using estradiol, due to the synthetic ethinyl estradiol component and elevated VTE risk. The video's recommendation to transition to standard HRT when symptoms are uncontrolled or at age 50 aligns with NAMS and British Menopause Society guidance, though individual cardiovascular risk stratification is essential before initiating or continuing COCs in women over 40. The Mirena IUD as a progestin source in combination with systemic estrogen is a well-documented clinical strategy for women requiring concurrent contraception.
  • COCs use synthetic ethinyl estradiol, not estradiol. The Lidegaard et al. (2009, BMJ) MEGA study documented significantly higher VTE risk with combined pills compared to non-use, a distinction absent from this video.
  • NAMS 2022 guidelines confirm low-dose COCs are an acceptable perimenopausal option for vasomotor symptom control in women without contraindications, supporting the video's core premise.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • COCs use synthetic ethinyl estradiol, not estradiol. The Lidegaard et al. (2009, BMJ) MEGA study documented significantly higher VTE risk with combined pills compared to non-use, a distinction absent from this video.
  • NAMS 2022 guidelines confirm low-dose COCs are an acceptable perimenopausal option for vasomotor symptom control in women without contraindications, supporting the video's core premise.
  • Smoking is an absolute contraindication to COC use in women over 35 due to stroke and clot risk. This was not mentioned in the video and is a meaningful omission for a broad audience.
  • The Mirena IUD as a progestin delivery method alongside systemic estrogen is guideline-supported by both the British Menopause Society and documented in peer-reviewed literature since the late 1990s.
  • Confirming menopause after stopping COCs requires FSH testing on pill-free days, since COCs suppress the hormonal signals used to diagnose menopause. This practical point was not addressed.
  • ACOG's 2017 committee opinion notes healthy, non-smoking perimenopausal women may use COCs up to age 50-55, but requires individual cardiovascular and thromboembolic risk assessment, not a blanket age threshold.
  • Traditional menopausal HRT uses lower doses of estradiol rather than synthetic ethinyl estradiol, which carries a more favorable risk profile for older perimenopausal women, according to comparative analyses in Climacteric (Stevenson et al., 2013).

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @pagingdrfran actually say?

The claim here is straightforward: combined hormonal birth control pills can function as a "three-in-one" hormone replacement during perimenopause, delivering estrogen for symptom control, progestin for uterine protection, and contraception against pregnancy. She also argued that women under 50 whose symptoms aren't controlled by the pill should transition to traditional HRT, and that a Mirena IUD can serve as the progestin component when adding an estrogen patch or pill. The age-50 mark, she said, is a common inflection point for switching.

This is a clinically grounded take. She's not selling anything exotic, and she's not overstating the evidence. The framing is pragmatic and reflects how a lot of ob-gyns and menopause specialists actually practice.

Does the science back this up?

Mostly, yes. The use of combined oral contraceptives (COCs) in perimenopausal symptom management is supported by professional guidelines, though with important caveats around risk stratification. The evidence for transitioning to traditional HRT around age 50 is also solid, though the reasoning is more nuanced than the video lets on.

The North American Menopause Society (NAMS) 2022 position statement confirms that low-dose COCs are an acceptable option for managing vasomotor symptoms in perimenopausal women without contraindications. The estrogen dose in COCs (typically 20-35 mcg ethinyl estradiol) is pharmacologically higher than what's used in standard menopausal HRT, which is relevant to risk. Goldstein et al. (2011, Menopause) documented that COCs suppress endogenous hormone fluctuations and can mask the transition to menopause, which is why the age-50 transition point matters clinically. The Mirena IUD as a progestin source alongside systemic estrogen is well-established in the literature, including work by Suvanto-Luukkonen et al. (1997, Maturitas) and is endorsed by the British Menopause Society.

What did they get right, and where does it get thin?

She got the broad strokes right. Yes, you can still get pregnant in perimenopause. Yes, COCs provide estrogen, progestin, and contraception simultaneously. Yes, transitioning to traditional HRT makes sense when symptoms aren't controlled or when age-related cardiovascular and thromboembolic risk starts to tip the scales. Credit where it's due.

The gaps are in what she didn't say. COCs carry a higher venous thromboembolism (VTE) risk than standard menopausal HRT, and that distinction matters for women over 40 with additional risk factors like smoking, hypertension, or migraine with aura. The MEGA study (Lidegaard et al., 2009, BMJ) documented significantly elevated clot risk with combined pills versus non-use. She also doesn't mention that traditional HRT uses estradiol rather than synthetic ethinyl estradiol, which has a meaningfully different metabolic and risk profile. The omission isn't reckless, but it's a real gap for a video that's reaching tens of thousands of people making actual healthcare decisions.

What should you actually know?

If you're perimenopausal and your doctor is recommending COCs for symptom management, that's a legitimate clinical option. But the conversation needs to include your individual cardiovascular and clotting risk profile, not just your age. COCs are not low-dose HRT. The estrogen is synthetic and the dose is higher, which changes the risk calculation.

The Mirena-plus-estrogen approach is a well-supported option for women who need contraception and symptom relief simultaneously. It's used widely in the UK and is gaining traction in US practice. The transition to standard HRT after 50 is generally sensible because COC risks increase with age and because confirming menopause status becomes relevant for adjusting treatment. A 2017 ACOG committee opinion also notes that healthy, non-smoking perimenopausal women can use COCs up to age 50-55, but individual risk assessment is required, not a blanket recommendation.

  • COCs use ethinyl estradiol, not estradiol. The difference in metabolic and clotting risk is real.
  • Smoking is an absolute contraindication to COC use over age 35. This was not mentioned.
  • Mirena IUD as progestin delivery alongside systemic estrogen is guideline-supported and effective.
  • Confirming menopause after stopping COCs typically requires FSH testing, since pills suppress the hormone signal.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Fran (DO, FACOG) · Instagram creator

31.7K views on this video

birth control pills for perimenopause…and when it’s time to switch to traditional hormone replacement therapy #perimenopause #birthcontrolpills #hormonereplacementtherapy #HRT #hotflashes

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about cocs use synthetic ethinyl estradiol, not estradiol. the lidegaard et?

COCs use synthetic ethinyl estradiol, not estradiol. The Lidegaard et al. (2009, BMJ) MEGA study documented significantly higher VTE risk with combined pills compared to non-use, a distinction absent from this video.

What does the video say about nams 2022 guidelines confirm low-dose cocs?

NAMS 2022 guidelines confirm low-dose COCs are an acceptable perimenopausal option for vasomotor symptom control in women without contraindications, supporting the video's core premise.

What does the video say about smoking?

Smoking is an absolute contraindication to COC use in women over 35 due to stroke and clot risk. This was not mentioned in the video and is a meaningful omission for a broad audience.

What does the video say about the mirena iud as a progestin delivery method alongside systemic?

The Mirena IUD as a progestin delivery method alongside systemic estrogen is guideline-supported by both the British Menopause Society and documented in peer-reviewed literature since the late 1990s.

What does the video say about confirming menopause after stopping cocs requires fsh testing on pill-free?

Confirming menopause after stopping COCs requires FSH testing on pill-free days, since COCs suppress the hormonal signals used to diagnose menopause. This practical point was not addressed.

What does the video say about acog's 2017 committee opinion notes healthy, non-smoking perimenopausal women may?

ACOG's 2017 committee opinion notes healthy, non-smoking perimenopausal women may use COCs up to age 50-55, but requires individual cardiovascular and thromboembolic risk assessment, not a blanket age threshold.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr. Fran (DO, FACOG), not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.